Bioengineered Protein Drugs Market Size To Cross USD 672.7 Billion By 2034, Growing At A CAGR Of 6.2% - Report By Transparency Market Research, Inc.
The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...
Fierce Biotech14h
Samsung backs Alzheimer's blood test developer C2N Diagnostics with $10M
Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...
PMLive18h
Biogen initiates phase 3 study of felzartamab in kidney transplant patients
Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...
TD Cowen Remains a Buy on Biogen (BIIB)
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Unleased lab space. Plunging valuations. Layoffs. In Massachusetts, the biotech slump is taking its toll.
There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.